---
title: "688319.SH (688319.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688319.SH/news.md"
symbol: "688319.SH"
name: "688319.SH"
parent: "https://longbridge.com/en/quote/688319.SH.md"
datetime: "2026-05-21T13:58:28.419Z"
locales:
  - [en](https://longbridge.com/en/quote/688319.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688319.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688319.SH/news.md)
---

# 688319.SH (688319.SH) — Related News

### [](https://longbridge.com/en/news/285295879.md)
*2026-05-06T01:53:13.000Z*
> The A-share innovative drug sector has fluctuated and strengthened, with TONGHUA GOLDEN-HORSE hitting the daily limit, O

### [Olymvax Biopharmaceuticals: The gold grape bacteria vaccine will be unblinded in the first half of this year, and we are confident in completing it on schedule](https://longbridge.com/en/news/283581126.md)
*2026-04-22T01:39:51.000Z*
> Olymvax Biopharmaceuticals stated at the 2025 annual shareholders' meeting that the unblinding of the gold grape bacteri

### [Directly hitting the Olymvax Biopharmaceuticals shareholders' meeting: The unveiling of the heavyweight gold-staphylococcus vaccine is imminent, the second indication is advancing, and there is still a need to break free from reliance on a single major product](https://longbridge.com/en/news/283580874.md)
*2026-04-22T01:37:19.000Z*
> Olymvax Biopharmaceuticals announced at the 2025 annual shareholder meeting that the Staphylococcus aureus vaccine has c

### [Olymvax Biopharmaceuticals: Net profit of 22.2601 million yuan in 2025, a year-on-year increase of 7.24%](https://longbridge.com/en/news/281039383.md)
*2026-03-30T14:25:28.000Z*
> Sina Finance reported on March 30 that Olymvax Biopharmaceuticals announced that it expects to achieve an operating inco

### [](https://longbridge.com/en/news/279520826.md)
*2026-03-18T02:25:11.000Z*
> The A-share innovative drug sector fluctuated upward, with HUALAN NPM and Rongchang Bio reaching intraday highs, VCANBIO

### [The innovative drug concept shows signs of partial recovery, Asieris hits a 20% limit up](https://longbridge.com/en/news/277729344.md)
*2026-03-04T05:44:19.000Z*
> In the afternoon, the innovative drug concept showed a partial rebound, with Asieris hitting the 20% daily limit, Allist

### [New Stock News | Olymvax Biopharmaceuticals plans Hong Kong IPO, the Securities Regulatory Commission requires clarification on whether the business involves the development and application of gene therapy technologies listed in the negative list](https://longbridge.com/en/news/277463150.md)
*2026-03-02T12:28:05.000Z*
> Olymvax Biopharmaceuticals plans to conduct an IPO on the Hong Kong stock market, but the China Securities Regulatory Co

### [Olymvax Biopharmaceuticals: Net profit of 22.2317 million yuan in 2025, a year-on-year increase of 7.10%](https://longbridge.com/en/news/277164935.md)
*2026-02-27T08:34:46.000Z*
> Olymvax Biopharmaceuticals released its performance report, achieving an operating income of 704 million yuan in 2025, a

### [The biopharmaceutical sector saw a short-term surge, with CCHT hitting the daily limit up](https://longbridge.com/en/news/276843462.md)
*2026-02-25T06:40:51.000Z*
> The biotechnology sector saw a short-term surge, with CCHT hitting the daily limit, Sunshine Guojian Pharmaceutical risi